Skyways Air Services and Symbiotec Pharmalab IPOs have recorded strong interest from retail and non-institutional investors on their final day of bidding. However, participation from Qualified Institutional Buyers remains muted, staying below the 1x threshold for both issues. Investors are watching for any last-minute institutional inflows before the books close, ahead of the September 1, 2026, listing.
The public offerings of Skyways Air Services and Symbiotec Pharmalab have entered their final day of bidding, revealing a distinct trend where retail and non-institutional investors (NIIs) are driving the subscription figures, while institutional interest remains conservative.
Skyways Air Services, a logistics company, has seen its offering heavily supported by the non-institutional segment. For context, the company faces operational challenges, including thin EBITDA margins, which hovered around 4.47% in recent periods. Additionally, investors should be aware of material risks, including ongoing legal and tax proceedings, such as an FIR filed by the Economic Offences Wing (EOW), and past losses reported at the subsidiary level. Despite these factors, the retail and NII segments have pushed the overall subscription, while Qualified Institutional Buyers (QIBs) have shown limited appetite so far, with coverage staying below 1x. The company priced its shares between ₹131 and ₹138 and raised ₹174.5 crore from anchor investors to support its growth plans.
Symbiotec Pharmalab, an Indore-based pharmaceutical firm, has also seen a similar divide in investor appetite. The company, which is seeking a valuation of approximately ₹6,350 crore, has attracted strong attention from retail and non-institutional investors. However, institutional participation has remained tepid. While the pharmaceutical sector often carries inherent regulatory and operational risks, the firm’s valuation and sector-specific volatility are factors that institutional investors typically scrutinize closely. The company secured ₹526.2 crore from anchor investors, and its price band is set at ₹938 to ₹988 per share.
The divergence between institutional and retail demand is a crucial monitorable. While strong retail and NII interest often signals high market sentiment, the lack of robust QIB participation can sometimes influence listing-day price volatility. Institutional buyers typically conduct deep financial analysis, and their cautious approach often reflects concerns regarding pricing, long-term margins, or sector-specific headwinds.
Both companies are scheduled to list on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) on September 1, 2026. For existing applicants and potential buyers, the primary focus will now shift to whether institutional investors participate in the final hours of the issue, as this often determines the price stability in the immediate secondary market trading sessions.